Google the history of the brca gene, research and tests around it. Its quite amazing.I hope all cancer research gets the pipeline it got.
Google the history of the brca gene, research and tests around it. Its quite amazing.I hope all cancer research gets the pipeline it got.
So saving a man's live fron prostate cancer means he dies at 75 instead of 70 and but saving a women's from breast cancer means she dies at 65 instead of 45.
That it's more common has probably made it easier to do research on once it gained sufficient visibility and funding.
http://onlinelibrary.wiley.com/doi/10.3322/caac.21332/full#c...
Right now breast cancer has a disproportionate amount of money spent on it, but I don't think comparing it to prostate cancer is fair.
Are you sure? It looks like they're both about 21 deaths per 100,000 people:
We're advancing it pretty fast though.
Edit: not to mention the perception of females as a weaker sex. Socially, society is mirroring male behavior in terms of protection of females. It'll switch and balance itself out in due time. Historically I think makes died more often to work or war, females to sickness. Today these boundaries are blurring, but (socio)evolution is a patient turtle.
"In addition, several OPDIVs have policies concerning the inclusion of women, minorities, and children as subjects in their grant-supported research. These policies, which implement Section 492B of the PHS Act, 42 U.S.C. 289 a-2, require that women and members of minority groups and their subpopulations be included in OPDIV-supported research projects involving human subjects, unless a clear and compelling rationale and justification establishes that inclusion is inappropriate with respect to the health of the subjects, the purpose of the research, or other circumstances. When these policies apply (as specified in the funding opportunity announcement), the applicant is required to address inclusion of these groups in the application narrative, and the applicant’s plans will be assessed as part of the objective (peer) review process. Failure to comply with this policy or to adequately address use of human subjects and animals may adversely affect the score for technical merit, which may result in the OPDIV not making an award."